Cargando…

Prevalence of hepatitis E infection in HIV/HCV-coinfected patients in Spain (2012–2014)

Hepatitis E virus (HEV) has emerged as a relevant pathogen for HIV-infected patients. However, there is scarce data on HEV infection in HIV/HCV-coinfected individuals with advanced fibrosis, which seems to increase the risk of HEV infection and worsen the prognosis of liver disease. We aimed to dete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vázquez-Morón, Sonia, Berenguer, Juan, González-García, Juan, Jiménez-Sousa, Ma Ángeles, Canorea, Isabel, Guardiola, Josep M., Crespo, Manuel, Quereda, Carmen, Sanz, José, Carrero, Ana, Hontañón, Victor, Avellón, Ana, Resino, Salvador
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361883/ https://www.ncbi.nlm.nih.gov/pubmed/30718554 http://dx.doi.org/10.1038/s41598-018-37328-6

Ejemplares similares

Dysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Status
por: Garcia-Broncano, Pilar, et al.
Publicado: (2018)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
por: Brochado, Óscar, et al.
Publicado: (2021)

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
por: Vigón, Lorena, et al.
Publicado: (2019)

HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients
por: Brochado-Kith, Óscar, et al.
Publicado: (2021)

Telomere Length Increase in HIV/HCV-Coinfected Patients with Cirrhosis after HCV Eradication with Direct-Acting Antivirals (†)
por: Molina-Carrión, Silvia, et al.
Publicado: (2020)

Successful HCV Therapy Reduces Liver Disease Severity and Inflammation Biomarkers in HIV/HCV-Coinfected Patients With Advanced Cirrhosis: A Cohort Study
por: Medrano, Luz Maria, et al.
Publicado: (2021)

FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients
por: Pineda-Tenor, Daniel, et al.
Publicado: (2014)

Stroke in HIV-infected individuals with and without HCV coinfection in Spain in the combination antiretroviral therapy era
por: Alvaro-Meca, Alejandro, et al.
Publicado: (2017)

Soluble Adhesion Molecules in Patients Coinfected with HIV and HCV: A Predictor of Outcome
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2016)

Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study
por: Guzmán-Fulgencio, María, et al.
Publicado: (2015)

Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
por: Fanciulli, Chiara, et al.
Publicado: (2022)

European mitochondrial haplogroups predict liver-related outcomes in patients coinfected with HIV and HCV: a retrospective study
por: Aldámiz-Echevarría, Teresa, et al.
Publicado: (2019)

Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
por: Pérez-Latorre, Leire, et al.
Publicado: (2018)

ADAR1 polymorphisms are related to severity of liver fibrosis in HIV/HCV-coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2017)

Mx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study
por: García-Álvarez, Mónica, et al.
Publicado: (2017)

Eradication of hepatitis C virus and non‐liver‐related non–acquired immune deficiency syndrome–related events in human immunodeficiency virus/hepatitis C virus coinfection
por: Berenguer, Juan, et al.
Publicado: (2017)

Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients
por: Medrano, Luz M., et al.
Publicado: (2016)

PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study
por: García-Broncano, Pilar, et al.
Publicado: (2014)

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant
por: Berenguer, Juan, et al.
Publicado: (2018)

Comparison of methods and characterization of small RNAs from plasma extracellular vesicles of HIV/HCV coinfected patients
por: Martínez-González, Elena, et al.
Publicado: (2020)

HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study
por: Ryan, Pablo, et al.
Publicado: (2021)

Perinatal HCV Transmission Rate in HIV/HCV Coinfected women with access to ART in Madrid, Spain
por: Domínguez-Rodríguez, Sara, et al.
Publicado: (2020)

NS3 Resistance-Associated Variants (RAVs) in Patients Infected with HCV Genotype 1a in Spain
por: Jimenez-Sousa, María Ángeles, et al.
Publicado: (2016)

All‐oral direct‐acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real‐world practice: Madrid coinfection registry findings
por: Berenguer, Juan, et al.
Publicado: (2018)

Endemic Circulation of European Bat Lyssavirus Type 1 in Serotine Bats, Spain
por: Vázquez-Morón, Sonia, et al.
Publicado: (2008)

Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics
por: Berenguer, Juan, et al.
Publicado: (2016)

Managing HCV/HIV coinfection
por: Danish, Fazal A., et al.
Publicado: (2009)

Pharmacologic management of HCV treatment in patients with HCV monoinfection vs. HIV/HCV coinfection: Does coinfection really matter?
por: Zuckerman, Autumn D., et al.
Publicado: (2019)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018
por: Pérez-Latorre, Leire, et al.
Publicado: (2021)

Trends in Epidemiology of COPD in HIV-Infected Patients in Spain (1997–2012)
por: de Miguel-Díez, Javier, et al.
Publicado: (2016)

Liver Stiffness Hinders Normalization of Systemic Inflammation and Endothelial Activation after Hepatitis C Virus (HCV) Eradication in HIV/HCV Coinfected Patients
por: Álvarez, Beatriz, et al.
Publicado: (2020)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

MicroRNA Profile of HCV Spontaneous Clarified Individuals, Denotes Previous HCV Infection
por: Brochado-Kith, Óscar, et al.
Publicado: (2019)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Liver Enzyme Alterations in HCV-Monoinfected and HCV/HIV-Coinfected Patients
por: Langohr, Klaus, et al.
Publicado: (2008)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Therapeutic issues in HIV/HCV-coinfected patients
por: Sulkowski, M S, et al.
Publicado: (2007)

Virological Mechanisms in the Coinfection between HIV and HCV
por: Liberto, Maria Carla, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ac8jbblqo0nbkdvk325eecukg6